24/7 Market News Snapshot 07 March, 2025 – PLUS THERAPEUTICS, Inc. Common Stock (NASDAQ:PSTV)

March 7, 2025

DENVER, Colo., 07 March, 2025 (247marketnews.com) – (NASDAQ:PSTV) are discussed in this article.
PLUS THERAPEUTICS, Inc. (PSTV) is currently experiencing a remarkable surge in its stock price, having risen by 49.24% to $2.149 in pre-market trading. This surge comes alongside an impressive trading volume of over 20 million shares, reflecting substantial investor interest and confidence in the company’s future prospects. Analysts are closely monitoring the situation as the developments signal potential growth opportunities for both current and future shareholders.

In a significant advancement for cancer treatment, Plus Therapeutics recently published the results of its Phase 1 clinical trial for Rhenium (186Re) Obisbemeda in the esteemed journal Nature Communications. This innovative injectable radiotherapy has shown promising safety and efficacy results in patients with recurrent glioblastoma (GBM), a notoriously aggressive brain cancer. Among the 21 participants in the trial, no dose-limiting toxicities were reported, and the adverse events were mostly unrelated to the therapy itself. With a median overall survival of 17 months reported for patients receiving over 100 Gy of the treatment, these results are particularly notable—more than double the standard care’s typical survival rate of 8 months.

Dr. Marc H. Hedrick, the President and CEO, highlighted the significance of these findings, expressing that the publication serves as a vital validation of their clinical endeavors. Currently, Plus Therapeutics is enrolling participants in its ReSPECT-GBM Phase 2 trial, aiming to provide a much-needed option for patients battling this challenging disease. By employing advanced targeted radiotherapy that focuses high radiation doses directly on tumor sites while minimizing collateral damage, Rhenium (186Re) Obisbemeda underscores the company’s dedication to innovative cancer treatment solutions. The ongoing trial represents a promising step forward in transforming the treatment landscape for recurrent glioblastoma, potentially offering hope to many patients in need.

Related news for (PSTV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.